Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

Objective Blood‐based biomarkers for neurodegenerative conditions could improve diagnosis and treatment development. Neurofilament light chain (NfL), a marker of axonal injury, is elevated in cerebrospinal fluid (CSF) of patients with progressive supranuclear palsy (PSP). The goal of this study was...

Full description

Saved in:
Bibliographic Details
Published in:Annals of clinical and translational neurology 2016-03, Vol.3 (3), p.216-225
Main Authors: Rojas, Julio C., Karydas, Anna, Bang, Jee, Tsai, Richard M., Blennow, Kaj, Liman, Victor, Kramer, Joel H., Rosen, Howard, Miller, Bruce L., Zetterberg, Henrik, Boxer, Adam L.
Format: Article
Language:English
Subjects:
Aging
Alzheimer's disease
Biomarkers
Brain research
Clinical trials
Dementia
Laboratories
Medical prognosis
Multiple sclerosis
Neurosciences
Neurovetenskaper
NMR
Nuclear magnetic resonance
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Blood‐based biomarkers for neurodegenerative conditions could improve diagnosis and treatment development. Neurofilament light chain (NfL), a marker of axonal injury, is elevated in cerebrospinal fluid (CSF) of patients with progressive supranuclear palsy (PSP). The goal of this study was to determine the diagnostic and prognostic value of plasma NfL in patients with PSP. Methods Plasma NfL was measured with ultrasensitive digital immunoassay‐based technology at baseline and 1‐year follow‐up in a pilot cohort of 15 PSP patients and 12 healthy controls, and a validation cohort of 147 PSP patients. Mixed linear models tested the ability of plasma NfL to predict neurological, cognitive and functional decline, and brain atrophy. Results Baseline mean plasma NfL levels were elevated in PSP patients (31 ± 4 pg/mL, vs. control, 17.5 ± 1 pg/mL, P 
ISSN:2328-9503
2328-9503
DOI:10.1002/acn3.290